Nuclear medicine at a crossroads

Journal of Nuclear Medicine

Volumn 52, Issue SUPPL. 2, 2011, Pages

  Schelbert, Heinrich R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Economics; Nuclear medicine; Trends

Indexed keywords

6 FLUORODOPA F 18; AMYLOID BETA PROTEIN; CARBON 11; ERLOTINIB; ESTRADIOL F 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GOLD NANOPARTICLE; INDIUM 111; INTEGRIN; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82; UNCLASSIFIED DRUG; YTTRIUM 90;

CANCER DIAGNOSIS; CLINICAL COMPETENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEALTH ECONOMICS; HEART MUSCLE PERFUSION; HUMAN; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; MEDICAL PRACTICE; MOLECULAR IMAGING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCARDIOGRAPHY; RADIODIAGNOSIS; REIMBURSEMENT; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

HUMANS; NUCLEAR MEDICINE; RADIOACTIVE TRACERS;

EID: 83755186015     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.085639     Document Type: Review

References (30)

1. Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle. 2010;9:3884-3886.
2. 18F-(2S,4R)-fluoroglutamine. J Nucl Med. 2011;52:1947-1955.
3. 11C]-glutamine for metabolic imaging of tumors. J Nucl Med. In press.
4. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2009;113:509-517.
5. 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study. J Nucl Med. 2011;52:1573-1579.
6. 2011 PET Imaging Market Summary Report. Greenbelt, MD: IMV; 2011.
7. 2011 Nuclear Medicine Market Outlook Report. Greenbelt, MD: IMV; 2011.
8. 2008 Nuclear Medicine Market Summary Report. Greenbelt, MD: IMV; 2008.
9. Friedman R. Nano dot technology enters clinical trials. J Natl Cancer Inst. 2011;103:1428-1429.
10. Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH. Cancer survivors: a booming population. Cancer Epidemiol Biomarkers Prev. 2011;20:1996-2005.
11. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117-128.
12. Emanuel EJ, Fuchs VR. The perfect storm of overutilization. JAMA. 2008;299:2789-2791. (Pubitemid 351846854)
13. Iglehart JK. Health insurers and medical-imaging policy: a work in progress. N Engl J Med. 2009;360:1030-1037.
14. Shaw LJ, Min JK, Hachamovitch R, et al. Cardiovascular imaging research at the crossroads. JACC Cardiovasc Imaging. 2010;3:316-324.
15. Levin DC, Rao VM, Parker L, Frangos AJ, Sunshine JH. Bending the curve: the recent marked slowdown in growth of noninvasive diagnostic imaging. AJR. 2011;196:W25-W29.
16. Yang Y, Czernin J. Contribution of imaging to cancer care costs. J Nucl Med. 2011;52(suppl):86S-92S.
17. Lee DW, Foster DA. The association between hospital outcomes and diagnostic imaging: early findings. J Am Coll Radiol. 2009;6:780-785.
18. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med. 2008;49:1928-1935.
19. Mac Manus MP, Hicks RJ. How can we tell if PET imaging for cancer is cost effective? Lancet Oncol. 2010;11:711-712.
20. Langer A. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res. 2010;10:283.
21. VanBrocklin HF. Radiopharmaceuticals for drug development: United States regulatory perspective. Curr Radiopharm. 2008;1:2-6.
22. Nunn AD. Molecular imaging and personalized medicine: an uncertain future. Cancer Biother Radiopharm. 2007;22:722-739.
23. Nunn AD. The cost of bringing a radiopharmaceutical to the patient's bedside [editorial]. J Nucl Med. 2007;48:169. (Pubitemid 47555337)
24. Guiberteau MJ, Graham MM. ACR-SNM Task Force on Nuclear Medicine Training: report of the task force. J Nucl Med. 2011;52:998-1002.
25. Coleman RE, Delbeke D, Guiberteau MJ, et al. Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the Joint Working Group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Am Coll Radiol. 2005;2:568-584. (Pubitemid 40884528)
26. Delbeke D, Graham M, Royal H, Segall G, Shulkin BL, Ziessman HA. Conjoint statement of the SNM, ACNM, and ABNM on credentialing and delineation of privileges for therapeutic procedures using radiopharmaceuticals. J Nucl Med. 2011;52:323-326.
27. Graham MM, Metter DF. Evolution of nuclear medicine training: past, present, and future. J Nucl Med. 2007;48:257-268. (Pubitemid 47555353)
28. Lucas RG Jr, Jacene H, Harolds J, Barnes L, Maurer A. Nuclear medicine training for radiology residents: needs assessment survey. Acad Radiol. 2007;14:301-305. (Pubitemid 46329448)
29. Larson SM. The Janus project: the remaking of nuclear medicine and radiology. J Nucl Med. 2011;52(suppl):3S-9S.
30. Zinn KR, Anderson CJ, Bradbury M, et al. Components of a curriculum for molecular imaging scientists. J Nucl Med. 2011;52:650-656.